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Abstract Purpose: Colon cancer is one of the most common human malignancies, yet studies have only
begun to identify the multiple mechanisms that underlie the development of this tumor. In this
study, we have identified a novelmechanism, dysregulationof endocytic sorting, whichpromotes
colon cancer development.
Experimental Design: Immunohistochemical and microarray analyses were done on human
colon cancer tissue specimens to determine the levels of one endocytic protein, sorting nexin 1
(SNX1). SW480 cells, a human colon cancer cell line that retains a relatively high level of SNX1
expression, were used to assess the effects of down-regulating this protein by small hairpin
RNA. Activation of signal transduction cascades was evaluated in these cells usingWestern
blotting, and multiple functional assays were done.
Results:We determined by immunohistochemistry that the level of SNX1was significantly
down-regulated in 75% of human colon cancers. In corroborative studies using microarray
analysis, SNX1message was significantly decreased (log2 ratio less than 1) for 8 of 19 colon
carcinomas. Cell lines with reduced SNX1 levels showed increased proliferation, decreased
apoptosis, and decreased susceptibility to anoikis. They also showed increased activation of
epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 in response to
epidermal growth factor.This increased activation was abolished by inhibition of endocytosis.
Conclusions: These data suggest that loss of SNX1may play a significant role in the develop-
ment and aggressiveness of human colon cancer, at least partially through the mechanism of
increased signaling from endosomes. Further, these findings suggest that dysregulation of endo-
cytic proteins may represent a new paradigm in the process of carcinogenesis.
Despite years of research, colon cancer remains a formidable
clinical problem. For the year 2005, colon cancer is estimated
to be the third most frequent cause of cancer deaths in both
men and women in the United States (1). Most studies
investigating the process of carcinogenesis center around signal
transduction cascades and their downstream effects on such
cellular processes as cell cycle regulation, apoptosis, and cell
migration. One cellular process that has received almost no
attention from cancer biologists is endocytic sorting. Receptors
internalized from the cell surface proceed first to the early
endosome, where each receptor is directed either back to the
surface to be reused or to the lysosome for degradation (2, 3).
Moreover, the early endosome is itself a location from which
activated receptors continue to signal (4–6). Proper receptor
sorting at this level ensures appropriate numbers of receptors
on the cell surface and accurate intensity of signaling from
endosomes and thereby ensures the necessary balance among
the signaling cascades downstream of these receptors. Con-
versely, dysregulation of receptor endocytosis may lead to
altered receptor signaling and ultimately to cancer.
In support of this hypothesis, we have evidence that one
endocytic protein, sorting nexin 1 (SNX1), is significantly
down-regulated during colonic carcinogenesis. The sorting
nexins comprise a large family of endocytic proteins that helps
determine the fate of internalized receptors as these receptors
reach the early endosome (7). Although the precise function of
the sorting nexins in not entirely clear, SNX1 may target
receptors to the lysosome for degradation (8). SNX1 has been
shown to interact with multiple receptor tyrosine kinases
[including the epidermal growth factor (EGF) receptor (EGFR),
the platelet-derived growth factor receptor-h, the insulin
receptor, the transferrin receptor, and the long form of the
leptin receptor (9)] and multiple receptor serine-threonine
kinases (10).
We hypothesized that the decreased SNX1 in colon cancer
results in the missorting of cell surface receptors, with
consequent alterations in receptor signaling in these cells and
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promotion of tumorigenesis. Immunohistochemical staining
of human colon cancers showed significant loss of SNX1 for
75% of the tumors. Microarray analysis of another 19 human
colon cancers showed significant down-regulation of SNX1
mRNA in 8 of these 19 cases. Using small hairpin RNA
(shRNA) depletion of SNX1 in SW480 cells, which retain SNX1
expression, we found that decreasing SNX1 led to increased
proliferation, decreased apoptosis, and decreased anoikis.
Moreover, reduction of SNX1 in these same cells resulted in
increased EGFR phosphorylation and increased downstream
signaling. This increase in mitogen-activated protein kinase
(MAPK) signaling in response to EGF could be abolished by
inhibition of endocytosis. This constellation of findings
suggests that SNX1 plays a significant role in the development
and manifestation of human colon cancer.
Materials andMethods
Human tissue specimens (immunohistochemistry samples). Human
normal and tumor tissue arrays were obtained (Biomeda, Foster City,
CA). Institutional Review Board approval was obtained to study
archival human colon cancer sections. We selected blocks of forma-
lin-fixed, paraffin-embedded colon carcinomas and normal colonic
tissue from 20 recent colonic resections for tumor. The only criteria
were that the cases be primary resections of invasive colonic adeno-
carcinomas with blocks available for staining. No further selection
criteria were applied.
Immunohistochemistry. Staining was done on 5-Am sections of
paraffin-embedded human adenocarcinomas. Antigen retrieval was
achieved by heating the slides in citrate buffer (pH 6.0; Biogenix, San
Ramon, CA). The slides were incubated in 1 Ag/mL SNX1 antibody
(Transduction Laboratories, Lexington, KY) for 45 minutes or in a 1:300
dilution of EGFR antibody (Cell Signaling Technology, Beverly, MA)
overnight. The slides were washed and incubated in a biotinylated
goat anti-mouse IgG or anti-rabbit IgG secondary antibody (1:200;
Vector Laboratories, Burlingame, CA) followed by 3% peroxide block.
After washing, the slides were developed using the avidin-biotin
complex method/3,3¶-diaminobenzidine detection kit (Ventana Medical
Systems, Tucson, AZ) followed by methyl green counterstain (DAKO,
Carpinteria, CA).
Patients and tissue samples (microarray samples). A total of 41 pairs
of colorectal cancer tissues and corresponding adjacent noncancerous
tissues was obtained from 41 patients with sporadic colorectal
adenocarcinoma who underwent surgical resection at the J. Mendez
Hospital and M.B. de Martinez Hospital (Buenos Aires, Argentina)
between May 2003 and June 2004. Only specimens containing >75%
tumor cells were used for analysis. Samples were macrodissected by
pathologists and, within 30 minutes of removal, frozen in liquid
nitrogen for molecular analysis.
RNA extraction and cDNA preparation. Total RNA was extracted
from frozen samples using Trizol reagent (Invitrogen Life Technologies,
Inc., Carlsbad, CA). Only 38 samples from our tumor bank that yielded
high-quality RNA with minimal degradation and clear 28S/18S
ribosomal bands were included in the analysis. Twenty-five tumors of
different clinical stages, in addition to 13 normal mucosa specimens,
were used for microarray experiments. Normal samples were pooled in
equimolar amounts to generate a single standard reference RNA used as
a control for each microarray hybridization. For half of the microarray
hybridizations, 50 Ag of total RNA isolated from each tumor sample
were retrotranscribed and labeled with Cy5-dCTP, and cDNA obtained
from 50 Ag of the standard reference RNA was labeled with Cy3-dCTP;
the fluorochromes were inverted in the second half of microarrays to
reduce dye bias.
Microarray hybridization and image acquisition. Hybridization
experiments were done on SS-Human 19Kv7 microarray (University
Health Network Microarray Centre, Toronto, Ontario, Canada).
Equivalent amounts of Cy5-cDNA and Cy3-cDNA were combined
and hybridized to microarray slides for 18 hours at 37jC. Hybridized
slides were scanned using the GenePix 4000a Scanner (Axon Instru-
ments, Foster City, CA), and images were acquired by GenePix Pro v5.0
software.
Data analysis. Twenty-five microarray data sets were sorted and
loaded on ExpressConverter v1.5 to transform GenePix generated result
files to the .mev file format for use with Microarray Data Analysis
System v2.18 software. Microarray Data Analysis System was used to
preprocess and normalize (within-slide LOWESS normalization) the
raw microarray data. The microarray data have been uploaded to
the Gene Expression Omnibus repository4 under the accession number
GSE3294.
Statistical methods. Using the log2 ratios of selected genes, the
reference list was generated by using Student’s t statistics calculated on
the full set of 21 patients. Significantly different expression between
tumor and normal mucosa was estimated using a one-class t test; the
P value of the gene was determined by forming a distribution based on
10,000 random permutations of the data. The P value for each gene was
scaled by adjusted Bonferroni correction to correct for the large number
of observations.
Cell culture. SW480, HT29, HCT116, HCT15, Moser, DLD-1, and
SW48 human colon cancer cells were grown according to the American
Type Culture Collection (Manassas, VA) recommended conditions.
shRNA preparation. Sequences to deplete SNX1 were modified from
Gullapalli et al. (11) to insert into the pSuperRetro vector. The specific
sequence used for the depletion (5¶-ACTCTAGTCAACCATAGGA-3¶) was
taken directly from SNX1 siRNA2 from Gullapalli et al. (11). A non-
silencing control shRNA oligonucleotide was also obtained (Qiagen,
Valencia, CA). Oligonucleotides were ligated into the pSuperRetro
vector (OligoEngine, Seattle, WA). The constructs were transfected
into SW480 cells. Puromycin (4 Ag/mL) was used to select multiple
stable clones.
Tritiated thymidine incorporation assay. SW480 control and SNX1
shRNA-transfected cells were plated in triplicate. Cells were pulsed with
1 ACi/mL tritiated thymidine (Amersham Biosciences, Piscataway, NJ)
for 3 hours, precipitated with 10% trichloroacetic acid, and solubilized
with 0.5 N sodium hydroxide before quantitation with a scintillation
counter.
Western blotting. Whole-cell lysates (10 Ag total protein) were
immunoblotted using antibodies against SNX1 (Transduction Labora-
tories). Whole-cell lysates (5 Ag total protein) were also immunoblotted
using antibodies against (Tyr1068) phosphorylated and total EGFR (Cell
Signaling Technology, Danvers, MA), phosphorylated extracellular
signal-regulated kinase (ERK) 1/2 (Sigma, St. Louis, MO), total ERK
1/2 (12), and g-tubulin (Sigma).
Active caspase-3 assay. Sixteen hours after plating, both adherent
and floating cells were collected, and protein lysates were prepared
as described previously (13). Protein (100 Ag) was incubated
with the fluorogenic caspase-3 substrate DEVD-AMC (BioMol,
Plymouth Meeting, PA) for 1 hour, and enzymatic activity was
determined as described previously (13). As a positive control for
apoptosis, AML-12 human hepatocyte cells were pretreated for 30
minutes with actinomycin D (250 ng/mL) followed by 15-hour
treatment with 20 ng/mL tumor necrosis factor (13).
Anoikis assay. The anoikis assay was modified from Frisch and
Francis (14). SW480 cells were cultured for 24 hours in plates coated
with poly-HEMA (Sigma) to prevent attachment. Nonadherent cells
were collected, rinsed with PBS, and lysed. Lysates were quantitated for
protein levels, and active caspase-3 was measured.
Inhibition of endocytosis. Endocytosis was reduced through either
depletion of potassium or incubation in a hypertonic medium as used
by Hansen et al. (15).
4 http://www.ncbi.nlm.nih.gov/projects/geo/.
Sorting Nexin1in Colon Cancer
www.aacrjournals.org Clin Cancer Res 2006;12(23) December1, 20066953
Results
SNX1 expression is down-regulated in human colon cancer. To
test the hypothesis that endocytic dysfunction plays a role in
tumorigenesis, we used an antibody against SNX1 to immu-
nostain both a normal and a tumor tissue array. Compared
with normal colonic tissue, the two colon carcinomas on the
array showed marked down-regulation in SNX1 expression
(data not shown). To assess larger areas and increased numbers
of normal and carcinomatous colon, we stained sections from
20 archival colon carcinomas and the adjacent normal colons
for SNX1. The average age of these patients was 66 F 12 years
(Supplementary Table S1). Thirteen of the patients were males
and 7 were females. The majority of the tumors were
moderately differentiated (13 of 20, 65%), and only one
tumor was poorly differentiated (5%). The average tumor size
was 3.6 F 2.0 cm. Lymph node metastases were present in 11
cases (55%) at the time of diagnosis.
The intensity of the SNX1 staining pattern was quantitated
as described in Supplementary Table S2. Normal colonic
epithelium shows a distinctly vesicular pattern when stained
with SNX1 (as is expected for a protein that associates with the
early endosome; Fig. 1A and B). Normal smooth muscle and
vascular endothelium show only minimal staining. Reactive
endothelial cells and macrophages stain strongly, with reactive
stroma often outlining malignant glands (Fig. 1C-F, asterisks).
Tumors (15 of 20, 75%) showed down-regulation of SNX1
staining (score of 0) when compared with the adjacent normal
epithelium (Supplementary Table S1). Figure 1 shows two
examples of this staining pattern, each example containing an
internal control of normal colonic epithelium. In Fig. 1C, the
left half of the image is composed entirely of malignant glands,
whereas the right half contains normal epithelium (except for a
single malignant gland that is apparent immediately adjacent to
the epithelium). In Fig. 1E, normal colon is present along the
bottom of the picture, whereas invasive tumor nodules are
notable within the submucosa.
Analysis of the relationships in Supplementary Table S1
illustrates more significant findings. Decreased SNX1 immu-
noreactivity correlated strongly with younger age (the average
age of the patients with a SNX1 score of 0 was 62, whereas
the average age of the patients with a SNX1 score of z1 was 77;
P < 0.01, two-tailed t test). Similarly, decreased immunoreac-
tivity for SNX1 correlated with male sex of the patient (P = 0.03,
Fig. 1. Loss of SNX1staining in colon
cancers. A and B, vesicular staining pattern
of SNX1in normal colonic epithelium.C to F,
two separate colon cancers are represented.
Normal epithelium shows vesicular brown
cytoplasmic SNX1staining.This staining is
nearly entirely absent from the tumor tissue.
B, D, and F, higher magnification views of
the boxes in (A), (C), and (E), respectively.
Asterisks, SNX1staining of reactive
stroma and activated endothelium. Original
magnification, 100 (A, C, and E) or400
(B, D, and F).
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Fisher’s exact test). These two associations may suggest that
decreased SNX1 immunoreactivity identifies a distinct subset of
human colon carcinomas. No association was noted between
SNX1 staining and tumor size or grade. No correlation was
identified between SNX1 immunoreactivity and the presence of
lymph node metastases.
Microarray analysis confirms SNX1 down-regulation in human
colon cancer. To confirm our immunohistochemical results
using a different modality, we compared samples of human
colon cancer with normal colonic epithelium by microarray
analysis. Tumor SNX1 message expression was less than control
for 18 of the 19 tumors. For 8 of these tumors, the log2 ratio
was less than 1. The average log2 ratio was 0.876, which was
significant at the level of P < 0.01.
The combination of these immunohistochemical and micro-
array data thus shows that down-regulation of SNX1 can be
detected in a substantial subset of human colon carcinomas at
the level of both transcription and protein expression. The
detection of this down-regulation through two unrelated
modalities argues strongly against the possibility of a technical
artifact and instead documents the validity of these results in
human colon tumors.
shRNA constructs deplete SNX1 in human colon cancer
cells. Mere down-regulation of a protein within a tumor does
not establish the significance of the protein for the develop-
ment of the tumor. To test the hypothesis that down-regulation
of SNX1 promotes colon tumorigenesis, we sought to
determine the effects of SNX1 depletion on colon tumor cells.
We screened seven colon cancer cell lines (SW480, HT29,
HCT116, HCT15, Moser, DLD-1, and SW48) for endogenous
SNX1 by Western blotting. We found that, of these cell lines,
SW480 cells contain the highest level of SNX1 (Fig. 2A). HT29,
HCT116, HCT15, Moser, and DLD-1 cells contain low but
detectable levels of SNX1 (Fig. 2A). SW48 cells contain only
minimal levels of SNX1 (Fig. 2A). Comparison with the results
of a tumor cell line microarray (Gene Expression Omnibus
accession GSD89) confirmed the SNX1 Western blotting (data
not shown). We then chose to continue our experiments in
SW480 cells using the only cell line that retained relatively high
levels of SNX1 expression. SNX1 was sequenced in this cell line
and was free of mutations (data not shown). Stable shRNA-
mediated depletion of SNX1 was established, and two clones
were selected for further experiments. Approximately 70%
inhibition was apparent in SW480 clone 1, and SW480 clone 3
showed even greater inhibition (f90%) compared with cells
stably transfected with a control shRNA construct (Fig. 2B).
Levels of SNX2, the most closely related sorting nexin to SNX1,
were unchanged by the depletion of SNX1 (Fig. 2B).
SNX1 down-regulated cells show increased proliferation,
decreased apoptosis, and decreased anoikis. To determine if
down-regulation of SNX1 affects the proliferation rate of these
tumor cells, the SW480 cell lines were assessed for their rates
of tritiated thymidine incorporation. The SW480 SNX1 shRNA
clones both showed significantly increased rates of proliferation,
Fig. 2. Down-regulation of SNX1in colon
cancer cell lines. A, seven cell lines were
assessed byWestern blotting for their
expression of SNX1. B, stable cell lines were
generated using a construct to deplete
SNX1 (cl lanes) and a nonsilencing control
shRNA construct (Con lanes).Two clones
were selected for further experiments:
clones1and 3 (cl1and cl3).Western blotting
was done to assess the expression of SNX1
and SNX2. g-Tubulin was used as a loading
control in allWestern blotting.
Fig. 3. Increased proliferation, decreased apoptosis, and decreased anoikis in
SNX1-depleted cells. A, proliferation was assessed through the incorporation of
tritiated thymidine. Representative studies from four separate experiments for clone
1and two separate experiments for clone 3. B, apoptotic rates were assessed using
a fluorescent assay to measure the activity of active caspase-3. Activity was
calculated as picomoles of cleaved fluorescent substrate per milligram cell lysate
protein per minute. Average results from three separate experiments for clone1and
two separate experiments for clone 3. C, anoikis assay.The ability of the cells to
survive in the absence of attachment was assessed. Poly-HEMAwas used to
prevent adherence of the cells to substrate, and active caspase-3 activity was
quantitated after 24 hours.White columns, control shRNA cells; black columns,
SNX1shRNA cells. Bars, SE. Statistical significance was determined using the
Student’s t test (two tailed).
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with clone 1 cells tripling and clone 3 cells more than
quadrupling their rate of tritiated thymidine incorporation
when compared with control shRNA cells (Fig. 3A).
Active caspase-3 assays were used to assess the steady-state
rates of apoptosis of these same stable cell lines. Control cells
had a moderately high basal rate of apoptosis, and these rates
were substantially reduced in both the clone 1 and clone 3
SNX1-depleted cells (Fig. 3B).
To assess the effect of SNX1 reduction on the ability of
these cells to survive in the absence of attachment to an
underlying substrate, an anoikis assay was done. SW480
control cells had a moderately high basal rate of anoikis, and
this rate was substantially reduced in both SNX1-depleted
clones (Fig. 3C).
Loss of SNX1 does not correlate with increased EGFR
expression. Because overexpression of SNX1 has been shown
to result in increased degradation of the EGFR (8), we initially
hypothesized that the corollary also holds true—that is, loss of
SNX1 results in decreased receptor degradation and therefore
increased receptor expression. To test this hypothesis, we
stained the cohort of tumor samples with an antibody against
the EGFR. The intensity of EGFR staining was scored according
to the scoring criteria described in Supplementary Table S2. The
results are detailed in Supplementary Table S1. For the majority
of the tumors (12 of 17), the intensity of the EGFR staining
was equal between the tumor and the surrounding normal
epithelium (Supplementary Table S1). Figure 4A and B shows
two representative sections of tumor and adjacent normal
epithelium in which the staining patterns are comparable. Most
significantly, the majority (11 of 14) of the tumors that showed
marked down-regulation of SNX1 (a SNX1 score of 0) showed
no change in EGFR levels (Fig. 4C). This finding suggests that
down-regulation of SNX1 in human tumors typically does not
lead to increased EGFR expression.
shRNA-mediated knockdown of SNX1 leads to increased EGFR
phosphorylation and increased ERK 1/2 signaling. Our func-
tional in vitro results (increased proliferation with decreased
apoptosis and anoikis following down-regulation of SNX1)
suggest that depletion of SNX1 increases the strength of EGF
signaling. In our tumor samples, however, EGFR levels did not
correlate with loss of SNX1. We similarly tested our SW480
SNX1-depleted cells, and they too showed no change in EGFR
levels compared with control shRNA cells (Fig. 4D). We then
hypothesized that reduction of SNX1 could still affect EGFR
signaling in the absence of increased receptor levels by altering
the dynamics of EGFR endosomal transport and signaling. To
begin to test this hypothesis, we first assessed both EGFR phos-
phorylation and downstream signaling through the ERK 1/2
pathway. For both clone 1 (Fig. 5A) and clone 3 (Fig. 5B),
reduced SNX1 levels resulted in increased EGFR phosphoryla-
tion. For confirmation, we used ERK 1/2 phosphorylation as a
sensitive marker for activation of this receptor tyrosine kinase
pathway. Cells with decreased SNX1 levels (both clone 1 and
clone 3) had a more robust and prolonged activation of this
kinase compared with cells stably expressing a control shRNA
construct (Fig. 5C and D). For each clone, quantitation of the
ratio of total ERK 1/2 to the loading control (g-tubulin) showed
a slightly higher level of total ERK 1/2 in the SNX1-depleted
cells than in the control cells. This difference was far less than
the difference in ERK phosphorylation between these cell lines,
however.
Reduction in endocytosis eliminates the differences in ERK 1/2
signaling. To test more definitively the hypothesis that
reduction of SNX1 alters the dynamics of EGFR endosomal
transport and signaling, we used two methods, potassium
depletion and use of a hypertonic medium (15), to minimize
the endocytosis of EGF-stimulated receptors from the cell
surface. We hypothesized that the downstream signaling we
Fig. 4. No change in EGFR levels in colon
cancers lacking SNX1. A and B, two
separate colon cancers. Arrowheads,
outline the regions of tissue involved by
tumor. Original magnification, 100.
C, distribution of EGFR staining scores for
those tumors with a SNX1score of 0 (no to
minimal SNX1staining). D, control shRNA
cells (Con lane), clone1cells (cl1lane),
and clone 3 cells (cl3 lane) were assessed
byWestern blotting for their expression of
the EGFR.
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then observed would derive from cell surface but not endo-
somally localized EGFRs. Because endosomally internalized
EGFR has been shown to signal preferentially through MAPK/
ERK cascades (16, 17), we further hypothesized that inhibition
of endocytosis would both decrease overall ERK 1/2 activation
and equalize the activation of the pathway between our cell
lines. Both techniques decreased EGF-stimulated ERK 1/2
activation for both clones (Fig. 6A and B for hypertonic sucrose
and Fig. 6C and D for potassium depletion). Moreover, both
techniques also eliminated the increased EGF-stimulated ERK
1/2 activation previously observed. Following inhibition of
endocytosis, both clones showed either equal or lesser ERK 1/2
activation than control cells.
Discussion
Among the most studied mechanisms underlying the process
of colon carcinogenesis are those affecting signaling cascades,
especially the Wnt, transforming growth factor-h, ras, and EGF
pathways (18, 19). Dysregulation of these pathways can occur
through several different mechanisms, including inactivating
mutations (transforming growth factor-h pathway), activating
mutations (Wnt and ras pathways), and increased surface
receptor levels (EGF pathway; refs. 18, 19). Alternatively, changes
in more general cellular processes, such as endocytosis, which
enhance receptor signaling pathways, may also facilitate carcino-
genesis. Here, we postulate that dysregulation of endocytic
sorting by loss of SNX1 contributes to colon cancer.
Our evidence strongly suggests that down-regulation of SNX1
is a significant factor in the development of the majority of
human colon cancers. We found that 75% of these tumors
showed immunohistochemical evidence of significant SNX1
reduction (Fig. 1). We then confirmed these immunohisto-
chemical results with microarray data that also showed
significant down-regulation of SNX1 mRNA in at least 8 of
19 human colon cancers. When human colon cancer cells
retaining SNX1 expression were depleted of this protein, they
showed multiple alterations, suggesting that they had deve-
loped a more aggressive phenotype. Down-regulation of SNX1
both increased proliferation (Fig. 3A) and decreased apoptosis
(Fig. 3B) in these tumor cells. In addition, decreased SNX1
protein resulted in decreased susceptibility to anoikis (Fig. 3C).
Taken together, these changes in vivo likely synergize to increase
the rate of tumor growth and may promote the ability of these
tumor cells to invade and metastasize.
Overall, our results strongly suggest that down-regulation of
SNX1 is a significant factor in the development and phenotypic
expression of human colon cancer, and they further suggest
that defects in endocytic sorting may represent an emerging
mechanism underlying the process of carcinogenesis. For
example, one proto-oncogene, Cbl, whose function has been
unknown until recently, has been found to regulate endocytic
sorting. The Cbl proto-oncogene has been shown to control the
sorting of endocytosed receptors through monoubiquitination
(20–22). Activating mutations of Cbl, which alter the endocytic
pathways taken by internalized receptors, are oncogenic.
Considerable evidence has developed recently suggesting that
endocytic processes directly regulate signaling pathways (4, 5).
Signaling is modulated when changes in receptor trafficking
alter one of two cellular properties. The first is cell surface
receptor levels; increased receptor levels, in the presence of the
appropriate ligand, lead to increased signaling. Because over-
expression of SNX1 has previously been shown to increase the
degradation of the EGFR (8), we initially hypothesized that our
Fig. 5. Increased EGFR phosphorylation
and ERK1/2 activation in SNX1-depleted
cells. A and B, control shRNA and clone1
(A) or clone 3 (B) cells were treated for
the indicated times with 20 ng/mLEGF.
Activation of EGFR was assessed using
a phosphorylation-specific antibody against
Tyr1068, which becomes a docking site for
growth factor receptor binding protein 2
when phosphorylated and thereby
promotes activation of the MAPK/ERK
pathway.C andD, control shRNA and clone
1 (C) or clone 3 (D) cells were treated for
the indicated times with 20 ng/mLEGF.
Activation of ERK1/2 was assessed using
phosphorylation-specific antibodies.
g-Tubulin was used as a loading control for
allWestern blotting.The intensity of the
Western blot signals was quantitated using
ImageJ software.White columns, control
shRNA cells; black columns, SNX1shRNA
cells. Columns, average results from two
independent experiments for each clone;
bars, SE.
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observation of a loss of SNX1 on colon tumors would correlate
with an increase in EGFR expression. We tested this hypothesis
by staining our colon cancer sections for EGFR expression. We
saw increased EGFR expression in 4 of 17 (24%) of the tumors
thatwe stained, a percentage on parwith recently reported results
for EGFR expression (23).Whenwe particularly examined the 14
of these cancers that showed down-regulation of SNX1, EGFR
expression was increased only for 2 (Fig. 4C). Although immu-
nohistochemistry is only a crude measure of surface receptor
levels, these data accord with our in vitro findings in our SNX1-
depleted cells (Fig. 4D) and with previous in vitro studies in
HeLa cells finding no change in EGFR levels with SNX1 down-
regulation (11, 24). In aggregate, these results suggest that
down-regulation of SNX1 increases EGFR signaling through a
mechanism independent of increased surface EGFR expression.
The second property that endocytic sorting can modulate to
influence signaling is the degree of signaling that takes place on
endocytic vesicles. It is nowwidely accepted that signaling occurs
not only from cell surface receptors but also from activated
receptors after they have been endocytosed (4–6). Changes in
endocytic trafficking may affect signaling (and therefore
tumorigenesis) not only by altering cell surface receptor levels
but also by modifying the transit of these proteins through the
cytoplasm, with resulting modulation in their intracytoplasmic
signaling characteristics, independent of the number of surface
receptors. That is, cells with the same number of cell surface
receptors may show different signal fluxes for a given ligand due
to differences in the degree of endosomal signaling. Our studies
clearly show that down-regulation of SNX1 leads to increased
EGFR phosphorylation (Fig. 5A and B) and increased ERK 1/2
signaling (Fig. 5C and D) in response to EGF. To test the
significance of the signaling from endosomes, we inhibited
endocytosis in our cell lines. Limitation of EGF stimulation to
cell surface receptors reduced overall ERK 1/2 signaling and
specifically equalized ERK 1/2 signaling between our control and
SNX1-depleted cells (Fig. 6), suggesting that the previously
observed increase in ERK 1/2 activation in SNX1-depleted cells
was derived from increased endosomal EGFR signaling.
In summary, we have identified SNX1 as a protein markedly
down-regulated in the majority of human colon cancers.
shRNA-mediated depletion of this protein from a human
colon cancer cell line results in a more aggressive tumor
phenotype, including increased proliferation with decreased
susceptibility to apoptosis and anoikis. These data suggest that
loss of SNX1 may play a significant role in the development
and manifestation of human colon cancer, and they further
suggest that dysregulation of endocytic proteins may represent a
new paradigm in the process of carcinogenesis.
Fig. 6. Equalization of ERK1/2 activation
following inhibition of endocytosis.
Hypertonic sucrose medium (A and B) or
depletion of potassium (C andD) was used
to inhibit endocytosis following EGF
stimulation. Control shRNA and clone1
(A and C) or clone 3 (B and D) cells
were treated for the indicated times with
20 ng/mL EGF. Activation of ERK1/2 was
assessed using phosphorylation-specific
antibodies. g-Tubulin was used as a loading
control for allWestern blotting.The intensity
of theWestern blot signals was quantitated
using ImageJ software.White columns,
control shRNA cells; black columns, SNX1
shRNA cells. Columns, average results from
two independent experiments for each
clone; bars, SE.
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